Point72 Asset Management
IONS icon

Point72 Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Point72 Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
20,000
+5,900
+42% +$466K ﹤0.01% 2502
2025
Q4 		$1.12M Buy
+14,100
New +$1.06M ﹤0.01% 2811

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's IONS Position: Q3 2025 in Review

Point72 Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 292,647 shares — an estimated $11.6M sold.

Point72 Asset Management first reported a position in IONS in Q2 2015 and held it in 22 quarters. The position peaked at $49M in Q4 2023. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

  • Point72 Asset Management reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 292,647 Ionis Pharmaceuticals shares in Q3 2025, an estimated $11.6M.
  • Point72 Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 22 quarters.
  • Point72 Asset Management's Ionis Pharmaceuticals position peaked at $49M in Q4 2023.
  • 435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.